Noticias y eventos de Fulgent Genetics Inc (FLGT)FLGTFulgent Genetics Inc

Ming Hsieh Reports Q2 Revenue of $85.4M

Reports Q2 revenue $85.4M, two estimates $91.77M. Ming Hsieh, Chairman of the Board of Directors and Chief Executive Officer, said, "In the second quarter, we had the honor of presenting the encouraging findings from Phase 2 data for FID-007 at the 2026 American Society of Clinical Oncology (ASCO) meeting, and we are encouraged by our clinical trial progress for both FID-007 and FID-022. We continue to execute on our strategic initiatives in our laboratory services business as we expand our AI portfolio and integrate digital pathology and are seeing a real impact from our AI tools with improved efficiency and quality."

Cuts FY26 Revenue Outlook to $330M-$340M

Two estimates ($1.57). Cuts FY26 revenue view to $330M-$340M from $350M, two estimates $350.93M.

Fulgent Genetics Updates Head and Neck Cancer Data at ASCO 2026

Fulgent Genetics "announced it presented updated data in the Head and Neck Cancer Track during the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting Rapid Oral Abstract Session, scheduled from 4:30 p.m. to 6:00 p.m. CDT in Hall D1 at McCormick Place in Chicago. The abstract, entitled "FID-007 in combination with cetuximab in recurrent or metastatic (R/M) head and neck squamous cell carcinoma, Abstract #6020," will present updated preliminary data from the Company's open-label, randomized Phase 2 study. The study is evaluating the efficacy of two dosing regimens and characterizing the pharmacokinetics, safety, and tolerability of FID-007 in combination with cetuximab in patients whose disease progressed following PD-1 based immune checkpoint inhibitor therapy. As of the April 16, 2026, data cutoff, FID-007 demonstrated meaningful clinical activity and a manageable safety profile in combination with cetuximab in this target patient population."